Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis
Who qualifies for our clinical trial?
Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis
Introduction to RejuvenAir®
The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.
CAUTION: Investigational device. Limited by Federal law to investigational use.
About COPD with Chronic Bronchitis
Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).
Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.
The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life. While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.
How Metered Cryospray Works
The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.
RejuvenAir rejuvenates the airways.
How Metered Cryospray Works
-196° C flash freeze causes instant cell death
Preservation of extracellular matrix (ECM)
Intact ECM enables healing with limited scarring and fibrosis
The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.
RejuvenAir rejuvenates the airways.
The SPRAY-CB Clinical Trial
Researching a NEW option for people living with Chronic Bronchitis
The RejuvenAir System Trial for COPD with Chronic Bronchitis (SPRAY-CB) is currently recruiting patients in the United States. This trial is designed to continue to explore the safety and effectiveness of metered cryospray treatments in patients suffering from Chronic Bronchitis.
Participation in the SPRAY-CB Trial
If you are wondering whether you or somebody you know might qualify to participate in this trial, we invite you to answer a short questionnaire; after which, we will let you know whether you might be a suitable candidate.
For more information, refer to the ClinicalTrials.gov website. Details are available for the United States SPRAY-CB Study and a smaller European Study.
The RejuvenAir System is CE marked in the European Union and limited to investigational use in the United States and is currently not for sale.
Find out if you qualify
To proceed, select the participating study center nearest to you on the map. You will be taken to the www.spray-cb.com website. Here you can watch an educational video, complete a short questionnaire and, if qualified, register your details.
| Title | Address | Description |
|---|---|---|
Temple University | 1801 N Broad St, Philadelphia, PA 19122, USA | ENROLLING Principal Investigator: Dr. G.J. Criner, Interventional Pulmonology /Pulmonary Care. |
UC Davis Medical Center | 2279 45th St, Sacramento, CA 95817, USA | ENROLLING Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology /Pulmonary Care |
Find out if you qualify
To proceed, select the study center nearest to you from the list below . You will be taken to the www.spray-cb.com website. Here you can watch educational videos, complete a short questionnaire and, if qualified, register your details.
About Us
CSA Medical is currently conducting clinical studies with the RejuvenAir System. The clinical study aims to evaluate the effectiveness of the RejuvenAir System to reduce mucous production, cough, and inflammation in the Chronic Bronchitis patient population and to determine the extent of improvement in their overall health and quality of life.
News & Resources
CSA Medical wins CE Mark approval for RejuvenAir System
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...
Cryotherapy for COPD patients with Chronic Bronchitis approved in Europe
Published by RT Magazine Health officials in Europe OK’d CSA Medical’s cryotherapy system to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The system applies metered sprayed liquid nitrogen at -196 C to areas within the lungs through a...
CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System at the 2019 European Respiratory Society International Congress
BOSTON, Oct. 3, 2019 /PRNewswire CSA Medical, Inc., presented positive 12-month results of its feasibility study for the RejuvenAir Metered Cryospray™ system yesterday at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain. In the...
131 Hartwell Avenue
Lexington
Massachusetts 02421
CAUTION: Investigational device. Limited by Federal law to investigational use.